Merck’s $25 Billion Lifeline Is About to Expire — Here’s the Bold Plan to Replace It!

Merck & Co.’s fourth-quarter 2024 financial performance reflects a complex landscape of strength in some areas alongside challenges in others. The company’s overall revenue increased by 7% to $15.6 billion, or 9% when accounting for foreign exchange impacts, partly driven by robust performance in its oncology and Animal Health segments. This growth trajectory, supporting strong demand for innovative products like KEYTRUDA, contrasts with notable headwinds faced with GARDASIL, particularly in the Chinese market.